RU2015143475A - Продукт и способ лечения диареи - Google Patents

Продукт и способ лечения диареи Download PDF

Info

Publication number
RU2015143475A
RU2015143475A RU2015143475A RU2015143475A RU2015143475A RU 2015143475 A RU2015143475 A RU 2015143475A RU 2015143475 A RU2015143475 A RU 2015143475A RU 2015143475 A RU2015143475 A RU 2015143475A RU 2015143475 A RU2015143475 A RU 2015143475A
Authority
RU
Russia
Prior art keywords
receptor antagonist
pharmaceutical composition
patient
composition according
famotidine
Prior art date
Application number
RU2015143475A
Other languages
English (en)
Russian (ru)
Other versions
RU2015143475A3 (enExample
Inventor
II Рид Б. ХОГАН
Original Assignee
МАРЕГЕЙД АрЭкс, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by МАРЕГЕЙД АрЭкс, ЭлЭлСи filed Critical МАРЕГЕЙД АрЭкс, ЭлЭлСи
Publication of RU2015143475A publication Critical patent/RU2015143475A/ru
Publication of RU2015143475A3 publication Critical patent/RU2015143475A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
RU2015143475A 2013-03-14 2014-03-14 Продукт и способ лечения диареи RU2015143475A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361782608P 2013-03-14 2013-03-14
US61/782,608 2013-03-14
PCT/US2014/027323 WO2014152420A2 (en) 2013-03-14 2014-03-14 Product and method for treating diarrhea

Publications (2)

Publication Number Publication Date
RU2015143475A true RU2015143475A (ru) 2017-04-20
RU2015143475A3 RU2015143475A3 (enExample) 2018-02-27

Family

ID=50680150

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2015143475A RU2015143475A (ru) 2013-03-14 2014-03-14 Продукт и способ лечения диареи

Country Status (20)

Country Link
US (4) US9717726B2 (enExample)
EP (3) EP3269364B1 (enExample)
JP (4) JP6313417B2 (enExample)
KR (4) KR20180088514A (enExample)
CN (2) CN108939076A (enExample)
AU (3) AU2014239878B2 (enExample)
BR (2) BR122017004716A2 (enExample)
CA (1) CA2906005C (enExample)
DK (1) DK2968205T3 (enExample)
ES (2) ES2655505T3 (enExample)
HK (1) HK1247557B (enExample)
HU (1) HUE035201T2 (enExample)
IL (3) IL273377B2 (enExample)
MX (2) MX366329B (enExample)
MY (1) MY175326A (enExample)
PL (1) PL2968205T3 (enExample)
PT (1) PT2968205T (enExample)
RU (1) RU2015143475A (enExample)
WO (1) WO2014152420A2 (enExample)
ZA (1) ZA201708539B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
US20150132410A1 (en) * 2013-11-14 2015-05-14 Michael M. Jacobs Compositions and methods for the prevention and treatment of alcohol-induced hangover syndrome
US20180185356A1 (en) * 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea
IT201900012645A1 (it) * 2019-07-23 2021-01-23 Eros Zanotti Una composizione farmaceutica per l'uso nel trattamento delle chinetosi
CN112616320B (zh) * 2019-08-05 2024-04-05 株式会社日立高新技术 等离子处理装置
CN115515435A (zh) * 2020-02-11 2022-12-23 沃尔夫森医疗中心 有效治疗溃疡性结肠炎的方法
CN117280446A (zh) 2021-08-23 2023-12-22 株式会社日立高新技术 等离子处理装置以及等离子处理方法
WO2023049205A1 (en) 2021-09-22 2023-03-30 Hista Rx Llc Compositions and methods for treating and preventing interstitial cystitis

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5204118A (en) 1989-11-02 1993-04-20 Mcneil-Ppc, Inc. Pharmaceutical compositions and methods for treating the symptoms of overindulgence
US5096894A (en) * 1990-04-03 1992-03-17 Bristol-Myers Squibb Company Rice dextrin oral rehydration solution
AU7255094A (en) 1993-07-06 1995-02-06 Mcneil-Ppc, Inc. H2 antagonist-antihistamine combinations
US6264984B1 (en) * 1999-12-06 2001-07-24 Bristol-Myers Squibb Company Effervescent histamine H2 antagonist composition
US6656492B2 (en) * 2000-06-30 2003-12-02 Yamanouchi Pharmaceutical Co., Ltd. Quick disintegrating tablet in buccal cavity and manufacturing method thereof
CA2430292A1 (en) 2000-11-30 2002-06-06 The Bio Balance Corp. Preparation of compositions comprising bacterial strains and volatile plant extracts and therapeutic and industrial applications thereof
WO2003044023A1 (en) * 2001-11-23 2003-05-30 Janssen Pharmaceutica N.V. The use of anti-histaminics for acute reduction of elevated intracranial pressure
SE528789C2 (sv) 2004-09-10 2007-02-13 Sandvik Intellectual Property PVD-belagt skär av hårdmetall samt sätt att tillverka detta
US20070077300A1 (en) * 2005-09-30 2007-04-05 Wynn David W Oral compositions containing a salivation inducing agent
US20090312358A1 (en) 2006-03-22 2009-12-17 Trustees Of Boston University Method for management of diarrhea
US8207188B2 (en) 2006-04-07 2012-06-26 Michalis Nicolaou Treatment of diseases modulated by a H4 receptor agonist
US8207292B2 (en) 2007-02-12 2012-06-26 Michalis Nicolaou Treatment of COPD, gastro-esophageal reflux disease (GERD), food allergies and other gastrointestinal conditions and disorders ameliorated by proper histamine management using a combination of histidine decarboxylase inhibitors, LRA drugs, anti-H1 and/or anti-H2 drugs
US20070254050A1 (en) * 2006-05-01 2007-11-01 Quart Barry D Method for treatment of diarrhea-predominant irritable bowel syndrome
US20090042972A1 (en) * 2006-05-19 2009-02-12 Somaxon Pharmaceuticals, Inc. Methods of using low-dose doxepin for the improvement of sleep
CA2721133C (en) * 2007-04-13 2018-11-06 Somaxon Pharmaceuticals, Inc. Low-dose doxepin formulations and methods of making and using the same
US8263581B2 (en) 2009-07-03 2012-09-11 Jdp Therapeutics, Inc. Non-sedating antihistamine injection formulations and methods of use thereof
EP3415627A1 (en) 2012-11-13 2018-12-19 Codiak BioSciences, Inc. Delivery of therapeutic agent
US9717726B2 (en) 2013-03-14 2017-08-01 Maregade Rx, LLC Product and method for treating diarrhea
US20180185356A1 (en) 2016-12-23 2018-07-05 Maregade Rx, LLC Low dose product and method for treating diarrhea

Also Published As

Publication number Publication date
HK1247557B (en) 2020-07-03
KR20150139535A (ko) 2015-12-11
IL273377B1 (en) 2023-06-01
IL241372A0 (en) 2015-11-30
JP6790140B2 (ja) 2020-11-25
US20190038619A1 (en) 2019-02-07
KR101884506B1 (ko) 2018-08-01
HK1213205A1 (en) 2016-06-30
US11058681B2 (en) 2021-07-13
WO2014152420A3 (en) 2014-11-20
IL256300B (en) 2020-04-30
HUE035201T2 (hu) 2018-05-02
ZA201708539B (en) 2019-05-29
AU2019201412A1 (en) 2019-03-21
JP2021046400A (ja) 2021-03-25
WO2014152420A2 (en) 2014-09-25
US20140275116A1 (en) 2014-09-18
JP2018135340A (ja) 2018-08-30
BR122017004716A2 (pt) 2019-07-30
KR20180088514A (ko) 2018-08-03
EP3269364A1 (en) 2018-01-17
US10034875B2 (en) 2018-07-31
CA2906005A1 (en) 2014-09-25
EP3269364B1 (en) 2019-05-29
DK2968205T3 (da) 2017-11-27
IL241372B (en) 2018-06-28
PT2968205T (pt) 2018-01-05
BR112015022513A2 (pt) 2017-07-18
KR102449977B1 (ko) 2022-09-30
JP2016513692A (ja) 2016-05-16
EP3581205A2 (en) 2019-12-18
ES2655505T3 (es) 2018-02-20
EP2968205A2 (en) 2016-01-20
US20170049770A1 (en) 2017-02-23
MX366329B (es) 2019-07-05
US20220047583A1 (en) 2022-02-17
AU2014239878A1 (en) 2015-10-15
MX2015011885A (es) 2016-05-16
AU2014239878B2 (en) 2017-08-24
US9717726B2 (en) 2017-08-01
CN105324112A (zh) 2016-02-10
ES2743604T3 (es) 2020-02-20
JP2019089796A (ja) 2019-06-13
AU2017251701B2 (en) 2019-03-14
IL256300A (en) 2018-02-28
JP6473254B2 (ja) 2019-02-20
EP3581205A3 (en) 2020-03-25
JP6313417B2 (ja) 2018-04-18
IL273377B2 (en) 2023-10-01
IL273377A (en) 2020-05-31
KR20210021606A (ko) 2021-02-26
MX350814B (es) 2017-09-21
CN108939076A (zh) 2018-12-07
CN105324112B (zh) 2018-08-17
PL2968205T3 (pl) 2018-03-30
AU2017251701A1 (en) 2017-11-09
CA2906005C (en) 2021-12-28
KR20200100211A (ko) 2020-08-25
MY175326A (en) 2020-06-19
EP2968205B1 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
JP2019089796A5 (enExample)
HRP20121072T1 (hr) Postupci za davanje tetrahidrobiopterina, povezani pripravci i postupci mjerenja
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
RU2017132877A (ru) Комбинация антагониста pd-1 и эрибулина для лечения рака
JP2014528901A5 (enExample)
UY32599A (es) Formulación oral sólida de abt-263
RU2015126661A (ru) Пероральная комбинация для предотвращения и лечения патологий мочевого пузыря, органов малого таза и мочеполового аппарата
RU2015134581A (ru) Доноры нитроксила с улучшенным терапевтическим индексом
RU2017134443A (ru) Способ лечения с применением традипитанта
RU2013106172A (ru) Композиция для снятия усталости, состав и их применение
RU2019134416A (ru) Фармацевтические композиции
RU2014137190A (ru) Комбинации ингибитора гистон-деацетилазы и пазопаниба и их применение
RU2015109566A (ru) НОВЫЕ ЭКСТРАКТЫ ИЗ CYNARA SCOLYMUS, COFFEA spp. И OLEA EUROPAEA ДЛЯ ЛЕЧЕНИЯ МЕТАБОЛИЧЕСКОГО СИНДРОМА
RU2015127834A (ru) Способы лечения диабета путем введения антагониста рецептора глюкагона в сочетании с ингибитором поглощения холестерина
RU2016109085A (ru) Применение иммунорегуляторного белка ганодерма (rlz-8) в получении лекарственного средства для лечения меланомы
RU2011111792A (ru) Применение парацетамола и ибупрофена в лечении
JP2012041314A5 (enExample)
RU2013126798A (ru) Комбинированная терапия дексаметазоном
CN102258485A (zh) 一种含对乙酰氨基酚的注射用制剂及其应用
EA201301049A1 (ru) Лекарственное средство
RU2016145411A (ru) Комбинация брекспипразола и налмефена, и ее применение для лечения синдрома химической зависимости
JP2017515858A5 (enExample)
RU2016143153A (ru) Комбинации противораковых лекарств
RU2014148062A (ru) Инъекционная фармацевтическая композиция декскетопрофена и трамадола
RU2017136693A (ru) Способы поддержания, лечения или улучшения когнитивной функции

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200730